Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 3/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | WDR5 | P61964 | 2/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29577102 | 1.00 | JAK1 (0.46) | JAK1CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL19210900 | 0.85 | JAK1 (0.46) | JAK1CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL29707393 | 0.85 | JAK1 (0.46) | JAK1CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL29577611 | 0.83 | JAK1 (0.45) | JAK1CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL21457806 | 0.83 | JAK1 (0.45) | JAK1CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL19210943 | 0.83 | TSHR (0.45) | TSHRALDH1A1HTTMAPTUSP30 | |
| SCHEMBL21457817 | 0.81 | JAK1 (0.48) | JAK1CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL29577318 | 0.81 | JAK1 (0.48) | JAK1CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL21457824 | 0.81 | JAK1 (0.43) | JAK1CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL29577303 | 0.81 | JAK1 (0.43) | JAK1CHRM2CHRM1CHRM3HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3414252-B1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO HEALTH INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11325917-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11325917-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| CN-109071560-B | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | 瓦洛健康公司 | 2022-01-14 | — | — | CN | disclosed |
| US-20210047343-A1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO HEALTH, INC. | 2021-02-18 | — | — | US | disclosed |
| US-20210047343-A1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO HEALTH, INC. | 2021-02-18 | — | — | US | disclosed |
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10889592-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-10889592-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| EP-3414251-B1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS INC (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-3414252-A1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| EP-3414251-A1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017139779-A1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017139778-A1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2017-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047343-A1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | USP25, USP28, USP30 | JAK1 390/4885CHRM2 4038/4885CHRM1 3445/4885 |
| US-11325917-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | USP25, USP28, USP30 | JAK1 390/4885CHRM2 4038/4885CHRM1 3445/4885 |
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | JAK1 523/4885CHRM2 2648/4885CHRM1 1973/4885 |
| US-10889592-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | USP25, USP28, USP30 | JAK1 390/4885CHRM2 4038/4885CHRM1 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.